Compounds for treating prostate cancer
A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R 20 —(Z) b —(Y) c —(R 21 ) a —X—R 22 —R 23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R 22 is a moiety that includes at least one divalent amino radical; R 23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provided that if X is —C(=0)- then Y is not S.
1. A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
R 20 —(Z) b —(Y) c —(R 21 ) a —X—R 22 —R 23
wherein R 20 is unsubstituted phenyl;
Z is alkanediyl or substituted alkanediyl;
Y is S;
R 21 is
X is —C(═O)— or —S(═O)(═O)—;
R 22 is
R 23 is a substituted phenyl having a structure of:
wherein each of R 1 -R 5 is individually H, alkyl, halogen, cyano, or substituted alkynyl, provided that R 1 is not H and R 4 is halogen;
a is 1;
b is 0 or 1; and
c is 0 or 1;
provided that if X is —C(═O)— then Y is not S.
2. The compound of claim 1 , wherein R 4 is chloro.
3. The compound of claim 1 , wherein b and c are each 0, and X is —C(═O)—.
4. The compound of claim 1 , wherein X is —C(═O)—.
5. The compound of claim 1 , wherein the compound is
6. A pharmaceutical composition comprising at least one pharmaceutically acceptable additive and a compound of claim 1 .
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutically acceptable additive is selected from physiological saline, balanced salt solution, aqueous dextrose, glycerol, mannitol, lactose, starch or magnesium stearate.
8. A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
R 20 —(Z) b —(Y) c —(R 21 ) a —X—R 22 —R 23
wherein R 20 is unsubstituted phenyl;
Z is alkanediyl or substituted alkanediyl;
Y is S;
R 21 is
X is —C(═O)— or —S(═O)(=O)—;
R 22 is
R 23 is a substituted phenyl having a structure of:
wherein each of R 1 -R 5 is individually H, alkyl, halogen, cyano, or substituted alkynyl, provided that R 1 is alkyl, halogen or cyano and R 4 is halogen;
a is 1;
b is 0 or 1; and
c is 0 or 1;
provided that if X is —C(═O)— then Y is not S.
9. The compound of claim 8 , wherein R 1 is methyl.
10. The compound of claim 8 , wherein b and c are each 0, and X is —C(═O)—.
11. The compound of claim 8 , wherein X is —C(═O)—.
12. A pharmaceutical composition comprising at least one pharmaceutically acceptable additive and a compound of claim 8 .
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable additive is selected from physiological saline, balanced salt solution, aqueous dextrose, glycerol, mannitol, lactose, starch or magnesium stearate.
14. A pharmaceutical composition comprising at least one pharmaceutically acceptable additive and a compound of claim 2 .
15. The pharmaceutical composition of claim 14 , wherein the pharmaceutically acceptable additive is selected from physiological saline, balanced salt solution, aqueous dextrose, glycerol, mannitol, lactose, starch or magnesium stearate.